VERTEX PHARMACEUTICALS INC (VRTX)
Sector: Health Care
2026 Annual Meeting Analysis
VERTEX PHARMACEUTICALS INC · Meeting: May 13, 2026
Directors FOR
11
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Independent director with deep biomedical engineering and academic research expertise; no overboarding, attendance above 90%, and the 3-year TSR gap of -20pp vs. the S&P 500 (^GSPC) falls well short of the 65pp threshold required to trigger an against vote for a strong-positive absolute TSR company.
Independent director with extensive CEO and technology leadership experience; holds two outside public board seats (Visa and Grid Dynamics) which is within the policy limit, attendance above 90%, and TSR trigger does not apply.
Independent director with deep expertise in healthcare economics and public policy; no other public board seats, attendance above 90%, and TSR trigger does not apply.
CEO and executive director with direct operational knowledge of the company; no outside public board seats, attendance above 90%, and the 3-year TSR gap of -20pp vs. the S&P 500 (^GSPC) falls well short of the 65pp threshold required to trigger an against vote.
Independent director with deep pharma services and manufacturing expertise; joined in 2023 (within 24-month exemption window relative to the 3-year TSR measurement period), no other public board seats, and attendance above 90%.
Executive Chairman and long-tenured director with unparalleled company-specific knowledge as a former CEO; no outside public board seats, attendance above 90%, and the 3-year TSR gap of -20pp vs. the S&P 500 (^GSPC) falls well short of the 65pp threshold required to trigger an against vote.
Independent director with extensive technology, cybersecurity, and healthcare industry leadership experience; holds two outside public board seats (MetLife and agilon health) which is within the policy limit, attendance above 90%, and TSR trigger does not apply.
Lead Independent Director with nearly three decades of board service and strong venture capital and CEO background; no other public board seats, attendance above 90%, and the 3-year TSR gap of -20pp vs. the S&P 500 (^GSPC) falls well short of the 65pp threshold.
Independent director who joined in 2024 and is exempt from the TSR trigger under the 24-month new-director exemption; brings relevant healthcare technology and physician leadership expertise with no other public board seats.
Independent director who joined in 2023 and whose tenure falls within the period where proportional application applies; holds two outside public board seats (Denali and Schrödinger) which is within the policy limit, attendance above 90%, and the TSR gap does not meet the trigger threshold.
Independent director and Audit Committee chair with extensive CFO and financial expertise across the pharma and medical device sectors; no other public board seats, attendance above 90%, and TSR trigger does not apply.
All eleven director nominees receive a FOR vote. Vertex's 3-year stock return of +39.6% is solidly positive, and the gap versus the S&P 500 benchmark (^GSPC) of -20 percentage points falls well below the 65-percentage-point threshold required to trigger an against vote for a company with strong-positive absolute returns. No director is overboarded, all directors met the 90%+ attendance standard, no independence concerns were identified on audit or compensation committees, and no familial relationships with senior management were found among independent directors.
Say on Pay
✓ FORCEO
Reshma Kewalramani
Total Comp
$21,144,261
Prior Support
92%%
CEO total compensation of approximately $21.1 million is within a reasonable range for a large-cap biopharma company of Vertex's size and complexity (~$111 billion market cap), with approximately 90% of executive pay tied to performance through annual cash bonuses and stock awards that vest only upon meeting specific financial and pipeline milestones — well above the 50-60% variable pay threshold required by policy. Although Vertex's 3-year stock return of +39.6% trailed the S&P 500 (^GSPC) by about 20 percentage points, this gap is not severe enough on its own to indicate a broken pay-for-performance link, especially given strong underlying business results including 9% revenue growth to $12 billion, successful product launches, and above-target incentive payouts tied to pre-set measurable goals. The prior year Say on Pay vote received 92% support, the compensation program includes meaningful clawback provisions, and the committee reduced equity mix toward performance-based awards for 2026, all of which support a FOR vote.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
21 yrs
Audit Fees
$5,649,560
Non-Audit Fees
$1,532,200
Ernst & Young has served as Vertex's auditor since 2005, giving it approximately 21 years of tenure — below the 25-year threshold that would trigger a no vote. Non-audit fees (tax fees of $1,405,000 plus other fees of $127,200 = $1,532,200) represent about 27% of audit fees ($5,649,560), well below the 50% threshold that would raise independence concerns. No material restatements were identified, and Ernst & Young is a Big 4 firm fully appropriate for a $111 billion market cap company.
Stockholder Proposals
1 proposal submitted by shareholders
Proposal 5
Shareholder Proposal Regarding Shareholder Right to Act by Written Consent
John Chevedden is a well-known individual governance activist with a long track record of submitting legitimate governance-improvement proposals, and this policy treats his proposals as credible and worthy of evaluation on their merits. Written consent rights are a mainstream corporate governance mechanism that gives shareholders an additional tool to act between annual meetings without the high coordination cost of calling a formal special meeting — it is the kind of structural governance improvement our policy generally supports. While Vertex reduced its special meeting threshold from 40% to 25% in February 2025 (a positive partial step), a 25% threshold based on all outstanding shares remains a high bar in practice, and written consent at a simple majority threshold would provide meaningful supplementary protection for shareholders without displacing existing meeting rights.
Overall Assessment
The 2026 Vertex Pharmaceuticals annual meeting ballot presents a clean director slate with no TSR trigger concerns (the 3-year gap vs. the S&P 500 benchmark (^GSPC) of -20 percentage points is far below the 65-point threshold for a strong-positive TSR company), a straightforward auditor ratification with well-controlled non-audit fees and tenure below the 25-year threshold, and a Say on Pay program with strong performance linkage and 92% prior-year shareholder support. The one contested item is the John Chevedden written consent proposal, where the policy supports FOR based on the filer's credible governance track record and the mainstream nature of the governance right being requested, notwithstanding the board's opposition and its recent reduction of the special meeting threshold.
Compensation Peer Group
1 companies disclosed in 2026 proxy filing